Abstract 1175
Background
Gastric cancer that is generally diagnosed in advanced stages is the second leading cause of cancer-related death worldwide. Although chemotherapy has benefit on quality of life and overall survival (OS) in metastatic gastric cancer (MGC), OS usually remains less than a year. Here, the efficacy and tolerability of first-line chemotherapy in MGC patients aged 70 years and older was investigated
Methods
As a multicenter study of ASMO, 305 patients followed in 17 centers between 2005 and 2015 were included. Patients who were 70 years and older at the time of MGC diagnosis and who had received at least two cycles of chemotherapy in the first-line setting were evaluated retrospectively.
Results
The clinical and demographical features of the patients were presented in Table 1. Median age was 73 (min-max 70-90). Median follow-up time was determined as 8 months (min-max 1-78), median PFS as 6 months (95%CI: 5.2-6.7) and median OS as 10 months (95%CI: 8.4-11.6). Partial response was achieved in 26.2% and stable disease in 16.7% of the patients. The most common chemotherapy related grade 3-4 hematologic toxicity was neutropenia (22%). Poor ECOG performance status, history of surgical treatment and less number of metastatic organs had statistically significant benefit on PFS and OS (p
Conclusions
We observed that first-line chemotherapy was effective and tolerable in elderly patients. The chemotherapy regimen (multiple or single) and the dose reduction at the beginning did not affect treatment response. It is reasonable to choose the minimum toxic and maximum tolerable chemotherapy regimen. It will be more relevant to use physiological age evaluations like ECOG performance status than biological age in treatment decision.
Clinical trial identification
Legal entity responsible for the study
Anatolian Society of Medical Oncology (ASMO)
Funding
N/A
Disclosure
All authors have declared no conflicts of interest.